Global Diagnostic Nuclear Medicines Market Size By Type (Tc99m, F-18), By Application (Oncology, Cardiology), By Region, And Segment Forecasts, 2023 to 2032

The Global Diagnostic Nuclear Medicines Market was valued at USD 5.9 billion in 2023 and is projected to surpass USD 11.3 billion by 2031, growing at a CAGR of 8.5% during the forecast period from 2023 to 2031. This growth is fueled by increasing prevalence of chronic diseases, advancements in imaging technologies, and rising awareness of early and accurate disease detection. Diagnostic nuclear medicines are extensively used in cardiology, oncology, and neurology to assess organ function and detect abnormalities, playing a pivotal role in precision medicine and preventive diagnostics.

Drivers:

Rising Incidence of Chronic Diseases:

The growing burden of cardiovascular disorders, cancer, and neurological conditions is significantly boosting demand for advanced imaging modalities. Nuclear diagnostic techniques like PET and SPECT scans provide high accuracy, driving their integration into routine diagnostics.

Technological Advancements in Radiopharmaceuticals:

Breakthroughs in targeted radiotracers and the development of hybrid imaging systems (such as PET/CT and SPECT/CT) are enhancing image resolution and diagnostic accuracy, stimulating market expansion.

Increasing Investment in Healthcare Infrastructure:

Emerging economies are prioritizing healthcare upgrades and investing in nuclear medicine capabilities, opening up new markets and facilitating wider adoption of diagnostic nuclear imaging.

Restraints:

Short Half-life of Radiopharmaceuticals:

The rapid decay of radioactive isotopes requires on-site or nearby production facilities, which limits distribution in regions lacking such infrastructure.

Stringent Regulatory Approvals:

The complex and lengthy approval process for radiopharmaceuticals and imaging systems delays market entry and adds to R&D costs for manufacturers.

Opportunity:

Integration of AI in Diagnostic Imaging:

Artificial intelligence and machine learning are being integrated into nuclear imaging systems to improve image interpretation and workflow efficiency, providing a compelling opportunity for innovation and value-added services.

Untapped Potential in Asia-Pacific and Latin America:

With healthcare modernization underway and increasing government focus on early disease detection, these regions offer significant growth potential for diagnostic nuclear medicine.

Market by System Type Insights:

In 2023, the SPECT (Single Photon Emission Computed Tomography) segment led the market due to its cost-effectiveness and widespread availability. However, the PET (Positron Emission Tomography) segment is expected to witness the highest growth rate during the forecast period, driven by its superior imaging accuracy and increased use in oncology and neurology diagnostics.

Market by End-use Insights:

The Hospitals segment dominated the market in 2023, accounting for more than 45% of the revenue share, owing to high patient volumes, availability of advanced imaging infrastructure, and skilled professionals. Diagnostic centers are anticipated to experience rapid growth due to their flexibility, specialized services, and increasing demand for outpatient imaging.

Market by Regional Insights:

North America emerged as the largest regional market in 2023, driven by the early adoption of innovative imaging technologies, strong reimbursement policies, and presence of major players. Asia-Pacific is projected to grow at the fastest CAGR through 2031 due to increasing healthcare access, rising disease prevalence, and favorable government initiatives to expand nuclear medicine infrastructure.

Competitive Scenario:

Key players in the global diagnostic nuclear medicines market include GE Healthcare, Siemens Healthineers, Cardinal Health, Bracco Imaging S.p.A., Lantheus Holdings, Inc., Curium Pharma, Nordion Inc., and Advanced Accelerator Applications (a Novartis company). These companies are pursuing partnerships, R&D investments, and regulatory approvals to maintain competitive advantage.

Scope of Work – Global Diagnostic Nuclear Medicines Market

Key Market Developments:

2023: GE Healthcare launched a next-generation PET/CT scanner with AI-assisted reconstruction, offering improved image clarity and reduced scan time.

2024: Curium announced FDA approval of a novel radiopharmaceutical for prostate cancer imaging, enhancing diagnostic accuracy in early-stage detection.

2025: Siemens Healthineers partnered with major hospital chains in Asia to expand PET/CT infrastructure across secondary cities.

FAQs:

What is the current market size of the Global Diagnostic Nuclear Medicines Market?

The market was valued at USD 5.9 billion in 2023.

What is the major growth driver of the Global Diagnostic Nuclear Medicines Market?

Rising prevalence of chronic diseases and advancements in radiopharmaceuticals are the major growth drivers.

Which is the largest region during the forecast period in the Global Diagnostic Nuclear Medicines Market?

North America held the largest market share in 2023 and will maintain dominance through 2031.

Which segment accounted for the largest market share in the Global Diagnostic Nuclear Medicines Market?

The SPECT segment accounted for the largest market share in 2023.

Who are the key market players in the Global Diagnostic Nuclear Medicines Market?

Key players include GE Healthcare, Siemens Healthineers, Cardinal Health, Bracco Imaging, and Curium Pharma.